LEO Pharma will acquire the global product rights ... be worth considerably less than two years ago, as since then some products have lost patent protection. The transaction is expected to ...

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) have approved a change to the terms of the marketing authorisation for LEO Pharma’s Adtralza ...

The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for ...

Over 2024, LEO Pharma made significant progress ... introduction of competing products, exposure to product liability, supply disruptions, developments in raw material and other input costs ...

LEO Pharma will manage the distribution ... In 2024, the European Commission and the UK Medicines and Healthcare Products Regulatory Agency approved the therapy for two indications, making ...